304,504 Shares in Compass Therapeutics, Inc. $CMPX Purchased by Nuveen LLC

Nuveen LLC bought a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 304,504 shares of the company’s stock, valued at approximately $579,000. Nuveen LLC owned approximately 0.22% of Compass Therapeutics as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its holdings in Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics during the fourth quarter valued at approximately $27,000. Mariner LLC acquired a new stake in Compass Therapeutics during the fourth quarter valued at approximately $30,000. Squarepoint Ops LLC acquired a new stake in Compass Therapeutics during the fourth quarter valued at approximately $35,000. Finally, ProShare Advisors LLC boosted its holdings in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after purchasing an additional 9,451 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Price Performance

CMPX stock opened at $3.37 on Thursday. The company has a 50 day moving average price of $2.98 and a 200 day moving average price of $2.48. Compass Therapeutics, Inc. has a fifty-two week low of $1.27 and a fifty-two week high of $4.08. The stock has a market capitalization of $466.00 million, a PE ratio of -7.49 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, equities analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Guggenheim lifted their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday, August 12th. Finally, Raymond James Financial raised Compass Therapeutics to an “outperform” rating and set a $9.00 price objective on the stock in a report on Tuesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company. According to MarketBeat.com, Compass Therapeutics has a consensus rating of “Buy” and an average price target of $12.89.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.